

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : **Jen-Leih WU et al.**

Attorney Docket: **33151-188802**

Serial No.: **Not Yet Assigned**

Unit: **TO BE ASSIGNED**

Filed: **November 21, 2003**

Examiner: **TO BE ASSIGNED**

For: **TRANSGENIC FISH GERMLINE EXPRESSION DRIVEN BY LIVER FATTY ACID  
BINDING PROTEIN (L-FABP) GENE PROMOTER AND APPLICATIONS THEREOF**

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §1.56, 1.97, and 1.98**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the dictates of 37 C.F.R. § 1.56, 1.97, and 1.98, Applicant hereby submits an Information Disclosure Statement. The attached listing is submitted with the desire that the Examiner consider the information and that the references considered be printed on any resulting patent. It is respectfully requested that the Examiner indicate such consideration by enclosing an appropriately initialed copy of the enclosed form PTO-1449 with the next communication from the Patent Office.

The Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 22-0261. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Fei-Fei Chao, Ph.D.  
Attorney of Record  
Reg. No. 43,538

Date: November 21, 2003

Venable LLP  
575 7<sup>th</sup> Street, N.W.  
Washington, D.C. 20004  
(202) 344-8011

DCDocs2/500984

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				C mplete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	November 21, 2003
				First Named Inventor	Jen-Leih WU et al.
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	33151-188802
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	Not Yet Assigned
Filing Date	November 21, 2003
First Named Inventor	Jen-Leih WU
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	33151-188802

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	Dooley, Kimberly et al., Zebrafish: a model system for the study of human disease; Genetics of disease; pg. 252-256	
	AB	Simon, Theodore C., et al., Use of Transgenic Mice to Map cis-Acting Elements in the Liver Fatty Acid-binding Protein Gene (Fabpl) That Regulate Its Cell Lineage-specific, Differentiation-dependent, and Spatial Patterns of Expression in the Gut Epithelium and in the Liver Acinus; The Journal of Biological Chemistry; Vol. 268, No. 24, August 25, 1993, pg. 18345-18358	
	AC	Shin, Jordan T., From Zebrafish to Human: Modular Medical Models; Annu. Rev. Genomics Hum. Genet.; Vol. 3, pg. 311-340, 2002	
	AD	Grunwald, David J., Headwaters of the zebrafish - emergence of a new model vertebrate; Perspectives; Vol. 3, pg. 717-724, September 2002	
	AE	Briggs, Josephine P., The zebrafish: a new model organism for integrative physiology; Am J Physiol Regulatory Integrative Comp Physiol, Vol. 282, pg. R3-R9, 2002	
	AF	Zon, Leonard I., Zebrafish: A New Model for Human Disease; Insight/Outlook, Vol. 9, pg. 99-100, 1999	
	AG	Amatruda, James F., Zebrafish as a cancer model system; Cancer Cell, Vol. 1, pg. 229-231, April 2002	
	AH	Langenau, David M., Myc-Induced T Cell Leukemia in Transgenic Zebrafish; Science, Vol. 299, pg. 887-890, February 2003	
	AI	Her, Guor M., In vivo studies of liver-type fatty acid binding protein (L-FABP) gene expression in liver of transgenic zebrafish (Danio rerio); FEBS Letters, Vol. 538, pg. 125-133, 2003	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.